Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
VANI
Strong SellSinkerVivani Medical, Inc. · Healthcare · United States · $128M · Avg Vol: $252K/d
11
StockRankGet insider-trade alerts
Q
17
V
24
M
45
P/E (TTM)
—
ROE
-220.4%
D/E
0.9x
Dividend %
—
COMPANY DESCRIPTION
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.36 | -0.50 | -0.43 | -0.43 | — | -0.36 | -0.33 | -0.39 | — |
| Shares | 50.7M | 51.0M | 59.2M | 76.4M | +50.6% | 90.2M | — | — | — |
| Debt | 1.0M | 20.7M | 19.3M | 18.9M | 170.3% | 17.9M | — | — | — |
| Equity | 44.3M | 20.8M | 17.6M | 15.7M | -29.2% | — | — | — | — |
| Op CF | -18.8M | -23.7M | -20.8M | -24.3M | — | -25.3M | — | — | — |
| Inv CF | -0.3M | -0.9M | -0.6M | -1.2M | — | — | — | — | — |
| Fin CF | 63.4M | 0.1M | 19.1M | 23.3M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-3.8%
SMA 50SMA 200
Close
$1.25
RSI (14)
36.7
52W High
$1.92
From 52W High
0.7%
SCORE BREAKDOWN
Quality
17
ROIC
-84.8%8.5
ROE
-220.4%3.9
GP/Assets
—N/A
Op. Margin
0.0%38.1
FCF/Assets
-67.3%4.6
Piotroski
12.4
Int. Cover
—N/A
D/E Ratio
0.94x14.7
Current Ratio
3.25x58.4
Value
24
P/E (TTM)
—N/A
EV/EBITDA
-4.9x25.0
P/FCF
—N/A
P/B
7.0x18.8
P/S
—N/A
Div Yield
—N/A
Momentum
45
52W High %
65%43.5
RS 6M
-3%63.2
SMA 50/200
1.07x71.0
EPS Rev 4W
0.0%34.4
EPS Rev 12W
—N/A
EPS Improve
+3%24.1
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$128M
P/E (Forward)
-4.3x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VANI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VANI | Vivani Medical, Inc.(you) | $128M | 11 | Strong Sell |
| CNTB | Connect Biopharma Holdings Limited | $140M | 10 | Strong Sell |
| UNCY | Unicycive Therapeutics, Inc. | $144M | 12 | Strong Sell |
| ANIX | Anixa Biosciences, Inc. | $118M | 14 | Strong Sell |
| COYA | Coya Therapeutics, Inc. | $108M | 10 | Strong Sell |
| INDP | Indaptus Therapeutics, Inc. | $152M | 13 | Strong Sell |
| KPTI | Karyopharm Therapeutics Inc. | $168M | 11 | Strong Sell |
| BMEA | Biomea Fusion, Inc. | $125M | 16 | Strong Sell |
| RANI | Rani Therapeutics Holdings, Inc. | $118M | 7 | Strong Sell |
| HURA | TuHURA Biosciences, Inc. | $134M | 6 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%